---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-037602"
form_type: "8-K"
ticker: null
cik: "0001651407"
company_name: "Checkpoint Therapeutics, Inc."
filed_at: "2024-03-22T23:59:59+00:00"
generated_at: "2026-06-04T09:04:30.750533+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Checkpoint Therapeutics reports FY2023 net loss of $51.8M; BLA resubmission for cosibelimab targeted by mid-2024

## Summary
- Net loss $51.8M ($3.17 per share) vs $62.6M ($7.09) in FY2022; no revenue.
- Cash and equivalents $4.9M at Dec 31, 2023; Jan 2024 offering added $14.0M gross.
- R&D expenses $43.6M, down from $49.8M; G&A flat at $8.7M.
- CRL from FDA in Dec 2023 only cited CMO inspection issues; resubmission planned mid-2024.
- Appointed Dr. Amit Sharma to board; raised ~$47.6M via offerings in 2023-2024.

## SEC filing metadata
- accession: 0001104659-24-037602
- form_type: 8-K
- cik: 0001651407
- company_name: Checkpoint Therapeutics, Inc.
- filed_at: 2024-03-22T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1651407/000110465924037602/0001104659-24-037602-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1651407/000110465924037602/tm249333d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-037602
- JSON: https://secwatch.observer/filing/0001104659-24-037602.json
- Plain text: https://secwatch.observer/filing/0001104659-24-037602.txt

## Key facts
- Earnings Releases
  Checkpoint Therapeutics, Inc. reported full-year ended December 31, 2023 results: net income Net loss attributable to common stockholders for the year ended December 31, 2023, was $51.8 million, EPS ($3.17 per share).
  - Period: full-year ended December 31, 2023
  - Net income: Net loss attributable to common stockholders for the year ended December 31, 2023, was $51.8 million
  - EPS: ($3.17 per share)
  - Result: reported results
  source text: Checkpoint Therapeutics Reports Full-Year 2023 Financial Results and Recent Corporate Highlights
  evidence_url: https://www.sec.gov/Archives/edgar/data/1651407/000110465924037602/0001104659-24-037602-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.